Gencurix, Inc.

As of June 30, 2026, Gencurix, Inc. carries a market capitalization of 51.66B, placing it among publicly traded companies globally. Its enterprise value stands at 62.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Gencurix, Inc. has 23.43M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 4.88, and the price-to-book ratio stands at 4.10.

These figures are as of June 30, 2026. The EV/Sales ratio of 6.99 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 62.43B versus a market cap of 51.66B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Gencurix, Inc. maintains a current ratio of 0.48, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 86.21, indicating elevated leverage, while an interest coverage ratio of -5.07 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Gencurix, Inc. posted a negative return on equity (ROE) of -62.36, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.86, reflecting losses generated across the asset base. The company generates approximately 121.92M in revenue per employee across its workforce of 73.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.62 indicates how many times Gencurix, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Gencurix, Inc. recorded 233.51M in income tax expense. The company reported a pretax loss of -7.27B and -7.51B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on September 14, 2026, Gencurix, Inc.'s stock has gained approximately 22.77% over the past 52 weeks. The 50-day moving average sits at 1,736.34, while the 200-day moving average is 2,197.66.

Over the twelve months ended June 30, 2026, Gencurix, Inc. generated 8.93B in revenue and converted that into -7.51B in net income, yielding earnings per share of -379.83. EBITDA reached -4.04B, while operating income came in at -4.78B.

As of June 30, 2026, Gencurix, Inc. holds 97.24M in cash and equivalents against 10.87B in total debt, resulting in a net debt position of 10.58B. Total book value stands at 12.61B, with working capital of -9.44B providing operational flexibility.

Gencurix, Inc. produced -3.63B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -357.21M in capital expenditures, free cash flow totaled -3.99B - equivalent to -201.80 per share.

Over the twelve months ended June 30, 2026, Gencurix, Inc. posted a gross margin of 79.86, reflecting its pricing power and cost economics. The operating margin of -53.52 and net profit margin of -84.06 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -9.15: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.63, meaning Gencurix, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Gencurix, Inc.'s most recent stock split took place on March 7, 2023 with a 41:45 split ratio.

As of June 30, 2026, Gencurix, Inc. has an Altman Z-Score of -3.59, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.